Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.

Autor: EVERSON, G. T.¹ (AUTHOR), SHIFFMAN, M. L.² (AUTHOR), HOEFS, J. C.³ (AUTHOR), MORGAN, T. R.³ (AUTHOR), STERLING, R. K.² (AUTHOR), WAGNER, D. A.⁴ (AUTHOR), DESANTO, J. L.¹ (AUTHOR), CURTO, T. M.⁵ (AUTHOR), WRIGHT, E. C.⁶ (AUTHOR)

Publikováno v: Alimentary Pharmacology & Therapeutics. Mar2009, Vol. 29 Issue 5, p589-601. 13p. 1 Diagram, 4 Charts, 3 Graphs.

The Tolerability of Sof/VEL for 12 Weeks in >1000 Patients Treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies : An Integrated Safety Analysis

Autor: Shiffman, M. L., Brau, N., Bourgeois, S., Mathurin, P., Thuluvath, P. J., Fessel, W. J., Ryder, S., Gerken, Guido, Foster, G. R., Jacobson, I. M., Liu, L., Ding, X., McNally, J., Osinusi, A., Grabowski, C., Moon, S., Brainard, D., Subramanian, M.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=unidue___bib::28d53a5eeb22e9297e6e38badc44249d

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

Autor: Zeuzem, S., Rodríguez Torres, M., Rajender Reddy, K., Marcellin, P., Diago, M., Craxi, A., Pockros, P., Rizzetto, Mario, Bernstein, D., Shiffman, M. L., Lin, A., Tatsch, F., Hadziyannis, S.

It is unclear whether the current threshold for 'high' hepatitis C virus (HCV) RNA level (800,000 IU/mL) is optimal for predicting sustained virological response (SVR). We retrospectively analysed pretreatment HCV RNA levels and SVR rates in 1529 mon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8f8b22afca63521c78b4f7b6bee7b772
http://hdl.handle.net/10447/73535

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3

Autor: Shiffman M. L., Suter F., Bacon B. R., Nelson D., Harley H., Sola R., Shafran S. D., Barange K., Lin A., Soman A., Zeuzem S., Crawford D., Leggett L., Roberts S., Weltman M., Greenbloom S., Menon K., Bourliere M., Brissot P., Bronowicki J. P., Doffoel M., Hezode C., Marcellin P., Tran A., Zarski J. P., Avci O., Berg T., Potthoff O., Rasenack J., Ross O., von Wagner M., Ascione A., Brunetto M., Bruno R., Bruno S., Cane E., Aguilar J., Barcena R., Diago M., Enriquez J., Garcia Samaniego J., Moreno R., Planas R., Rincon D., Testillano M., Anand B., Bilir B. Bahri, Balan V., Bank L., Barranco E., Berg C., Bernstein D., Bloom J., Bonkovsky H., Box T., Brau N., Bzowej N., Cassidy W., Clain D., Corasanti J., Davis M., DeJesus E., Delich P., Esposito S., Etzkorn K., Flora K., Fried M., Fromm H., Ghalib R., Gibas A., Godofsky E., Gompf S., Gordon S., Gordon F., Hammond G., Harrison S., Herrera J., Ho S., Howell C., Joshi S., Keeffe E., Kranz K., Kwo P., Lake Bakaar G., Larson A., Levin A., Lok A., Lucey M., Lyons M., Malet P., Malik P., Manch R., Mehra S., Mihas A., Mikolich D., Morgan T., Muir A., Nguyen R., Nunes D., Nyberg L., O'Brien C., Pappas S., Pauly M., Pedrosa M., Perkel M., Person J., Pockros P., Post A., Poulos J., Powell R., Raj V., Reed A., Reindollar R., Riley T., Rodriguez Torres M., Rubin R., Sahagun G., Schmidt W., Sepe T., Shaw Stiffel T., Sheikh A., Sherman K., Smith C., Stevens D., Sulkowski M., Toro D., Torres E., Tran T., Tsai N., Wohlman R., Wright W., Wruble L., Younossi Z., BRILLANTI, STEFANO

BACKGROUND: Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin for 24 weeks. We conducted a large, randomized, multina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d06d4d125b5f21e735f5226014a1f0
http://hdl.handle.net/11365/1070791

Prospective Multicenter Clinical Evaluation of AMPLICOR and COBAS AMPLICOR Hepatitis C Virus Tests

Autor: Fried, M. W., Nolte, F. S., Polyak, S. J., Ferreira-Gonzalez, A., Shiffman, M. L., Schiff, E. R., Garrett, C. T., Gretch, D. R.

We conducted a multicenter clinical evaluation of the second versions of the manual AMPLICOR and the semiautomated COBAS AMPLICOR tests for hepatitis C virus (HCV) RNA (Roche Molecular Systems, Inc., Pleasanton, Calif.). The performance characteristi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55da4a84e45cb7b246b89fe8837dfb34